Radwa Ahmed Batran , Mohab Kamel , Ayman Bahr , Ahmed Khalil , Mohamed Elsokary
{"title":"Value-based healthcare in oncology: Can it drive transformative shifts in the Middle East and North Africa region?","authors":"Radwa Ahmed Batran , Mohab Kamel , Ayman Bahr , Ahmed Khalil , Mohamed Elsokary","doi":"10.1016/j.hlpt.2024.100939","DOIUrl":null,"url":null,"abstract":"<div><div>The shift from volume-driven healthcare to value-driven healthcare, or value-based healthcare (VBHC), emerged in the 1990s, prioritizing healthcare quality over quantity. VBHC enjoys support from various healthcare stakeholders, emphasizing patient-centric outcomes that resonate with individual health experiences. Cancer is a major global cause of death, with low- and middle-income countries (LMICs) bearing a significant burden, particularly in the Middle East and North Africa (MENA) region, which is expected to witness a surge in cancer cases due to conflicts, changing demographics, and environmental factors. The MENA oncology market is poised for growth, fueled by biomarkers and targeted therapies. However, the MENA region's diversity leads to disparities in cancer care access and outcomes. Countries throughout the MENA region are presently in the midst of a substantial transformation of their healthcare systems. A number of MENA nations have taken steps to transition towards value-based care, recognizing its potential to reduce healthcare costs, enhance the quality of healthcare services, and promote healthier lifestyles among the populace. This review aims to highlight the ongoing initiatives within the MENA region toward implementing value-based cancer care. It also underscores the challenges associated with this transition while presenting a pragmatic and viable plan for the widespread adoption of value-based cancer care in the MENA region.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"13 6","pages":"Article 100939"},"PeriodicalIF":3.4000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Policy and Technology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211883724001023","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
The shift from volume-driven healthcare to value-driven healthcare, or value-based healthcare (VBHC), emerged in the 1990s, prioritizing healthcare quality over quantity. VBHC enjoys support from various healthcare stakeholders, emphasizing patient-centric outcomes that resonate with individual health experiences. Cancer is a major global cause of death, with low- and middle-income countries (LMICs) bearing a significant burden, particularly in the Middle East and North Africa (MENA) region, which is expected to witness a surge in cancer cases due to conflicts, changing demographics, and environmental factors. The MENA oncology market is poised for growth, fueled by biomarkers and targeted therapies. However, the MENA region's diversity leads to disparities in cancer care access and outcomes. Countries throughout the MENA region are presently in the midst of a substantial transformation of their healthcare systems. A number of MENA nations have taken steps to transition towards value-based care, recognizing its potential to reduce healthcare costs, enhance the quality of healthcare services, and promote healthier lifestyles among the populace. This review aims to highlight the ongoing initiatives within the MENA region toward implementing value-based cancer care. It also underscores the challenges associated with this transition while presenting a pragmatic and viable plan for the widespread adoption of value-based cancer care in the MENA region.
期刊介绍：
Health Policy and Technology (HPT), is the official journal of the Fellowship of Postgraduate Medicine (FPM), a cross-disciplinary journal, which focuses on past, present and future health policy and the role of technology in clinical and non-clinical national and international health environments.
HPT provides a further excellent way for the FPM to continue to make important national and international contributions to development of policy and practice within medicine and related disciplines. The aim of HPT is to publish relevant, timely and accessible articles and commentaries to support policy-makers, health professionals, health technology providers, patient groups and academia interested in health policy and technology.
Topics covered by HPT will include:
- Health technology, including drug discovery, diagnostics, medicines, devices, therapeutic delivery and eHealth systems
- Cross-national comparisons on health policy using evidence-based approaches
- National studies on health policy to determine the outcomes of technology-driven initiatives
- Cross-border eHealth including health tourism
- The digital divide in mobility, access and affordability of healthcare
- Health technology assessment (HTA) methods and tools for evaluating the effectiveness of clinical and non-clinical health technologies
- Health and eHealth indicators and benchmarks (measure/metrics) for understanding the adoption and diffusion of health technologies
- Health and eHealth models and frameworks to support policy-makers and other stakeholders in decision-making
- Stakeholder engagement with health technologies (clinical and patient/citizen buy-in)
- Regulation and health economics
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
